Europe Bladder Cancer Therapeutics and Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Europe Bladder Cancer Therapeutics and Diagnostics Market is Segmented by Product (Therapeutics and Diagnostics), Cancer Type and Geography

Market Snapshot

Picture1 Europe Bladder Cancer Therapeutics and Diagnostics Market
Study Period: 2018 - 2026
Base Year: 2020
CAGR: 5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The increasing burden of bladder cancer is the major factor driving the market in the European region. According to the estimates of Globocan, bladder cancer ranks fifth among the most frequently diagnosed cancer types, with about 197,105 new cases predicted in 2018 for both sexes, representing around 5% of the total cases. Moreover, increasing awareness about bladder cancer and related therapies is fueling the growth of the European bladder cancer therapeutics and diagnostics market. Apart from these, factors, like increasing awareness about bladder diseases and available therapies and innovations in novel drug development, are also contributing to the growth of the market studied. However, various factors, such as rise in the number of patent expiration is estimated to impede the growth of the studied market.

Scope of the Report

The bladder is a muscular membranous sack in the lower part of the abdomen that receives urine from the kidneys and stores it until it is excreted from the body. The most common type of bladder cancer is transitional cell carcinoma, which begins in the urothelial cells that line the inside of the bladder. Urothelial cells are transitional cells, which can change shape and stretch when the bladder is full. A common sign or symptom of bladder cancer is the release of blood along with the excreted urine. This type of cancer is also called urothelial carcinoma. Other types of bladder cancer include squamous cell carcinoma and adenocarcinoma. Bladder cancer can often be diagnosed at an early stage, and can be treated easily at this stage.

By Product
By Therapeutics
Chemotherapy
Immunotherapy
Others
By Diagnostics
Cystoscopy
Bladder Ultrasound
Urinalysis
Others
By Cancer Type
Transitional Cell Bladder Cancer
Squamous Cell Bladder Cancer
Others
Geography
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe

Report scope can be customized per your requirements. Click here.

Key Market Trends

Chemotherapy Segment is Expected to Show Better Growth in the Forecast period.

Chemotherapeutics refers to the utilization of drugs to combat a certain disorder. Chemotherapy is the first choice for bladder cancer treatment. In bladder cancer, the drug is administered either intravesically or directly into the urinary bladder. The non-muscle invasive bladder cancer (NMIBC) treatment is generally performed by chemotherapy and BCG immunotherapy. There has not been much development on bladder cancer chemotherapeutic agents, during the past decade. Furthermore, the incidence of bladder cancer is high among the population, which is expected to drive the market over the forecast period.

Europe Bladder Cancer Therapeutics and Diagnostics Market 1

Competitive Landscape

The market studied is highly competitive and consists of a number of major players. Companies, like AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Novartis, Pfizer Inc., Sanofi SA, etc. hold a substantial market share in the European bladder cancer therapeutics and diagnostics market.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Awareness on Bladder Diseases and Available Therapies

      2. 4.2.2 Increasing Burden of Bladder Cancer

      3. 4.2.3 Innovations in Drug Development

    3. 4.3 Market Restraints

      1. 4.3.1 Rise in the number of Patent Expirations

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product

      1. 5.1.1 By Therapeutics

        1. 5.1.1.1 Chemotherapy

        2. 5.1.1.2 Immunotherapy

        3. 5.1.1.3 Others

      2. 5.1.2 By Diagnostics

        1. 5.1.2.1 Cystoscopy

        2. 5.1.2.2 Bladder Ultrasound

        3. 5.1.2.3 Urinalysis

        4. 5.1.2.4 Others

    2. 5.2 By Cancer Type

      1. 5.2.1 Transitional Cell Bladder Cancer

      2. 5.2.2 Squamous Cell Bladder Cancer

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 Europe

        1. 5.3.1.1 Germany

        2. 5.3.1.2 United Kingdom

        3. 5.3.1.3 France

        4. 5.3.1.4 Italy

        5. 5.3.1.5 Spain

        6. 5.3.1.6 Rest of Europe

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca PLC

      2. 6.1.2 Bristol-Myers Squibb Company

      3. 6.1.3 Eli Lilly and Company

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 GlaxoSmithKline PLC

      6. 6.1.6 Novartis International AG

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Sanofi SA

      9. 6.1.9 Endo International plc

      10. 6.1.10 Janssen Pharmaceutical Companies (Johnson & Johnson)

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Europe Bladder Cancer Therapeutics and Diagnostics Market market is studied from 2018 - 2026.

The Europe Bladder Cancer Therapeutics and Diagnostics Market is growing at a CAGR of 5% over the next 5 years.

F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, AstraZeneca PLC, Johnson & Johnson (Janssen Pharmaceutical), Endo International plc are the major companies operating in Europe Bladder Cancer Therapeutics and Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!